Joerg Holenz
YOU?
Author Swipe
Early start of opicapone in Parkinson’s disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations Open
Background Levodopa is the mainstay of Parkinson’s disease (PD) therapy, but its long-term use is often complicated by the development of motor fluctuations. While COMT inhibitors, such as opicapone, are routinely used for managing motor f…
Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial Open
Background While sleep disturbances are among the most frequent non-motor symptoms of Parkinson's disease (PD), there is a lack of evidence to support its treatment. Objective To evaluate the efficacy of opicapone 50 mg in treating sleep d…
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial Open
Background Catechol‐O‐methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa‐treated patients without moto…
View article: Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: <i>Post hoc</i> analysis of a phase III trial
Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: <i>Post hoc</i> analysis of a phase III trial Open
A post hoc analysis of data from Asian patients included in the study BIA‐2093‐304 was conducted to evaluate the long‐term safety/tolerability and efficacy of adjunctive eslicarbazepine acetate (ESL) in adult Asian patients with refractory…